Singtel Innov8, the corporate venturing arm of telecommunications firm Singtel, and chemicals producer Asahi Kasei yesterday backed a $24.5m series C round for US-based digital health technology provider AiCure.
Palisades Growth Capital led the round, which included Accelmed Growth Partners and SpringRock Ventures, as well as Baird Capital, New Leaf Venture Partners, Pritzker Group, Biomatics Capital, Tribeca Venture Partners and Silicon Valley Bank.
Founded in 2010, AiCure has developed artificial intelligence technology that assesses how patients respond to treatments in clinical trials and regular care. The platform aims to increase patient engagement, ensuring optimal behaviour during treatment.
The series C capital will accelerate commercial, engineering, and research and development activities.
AiCure completed a $15m series B round in 2017 led by Baird Capital, with participation from Silicon Valley Bank, New Leaf Venture Partners, Pritzker Group, Biomatics Capital and Tribeca Venture Partners.
New Leaf Venture Partners had earlier led a $12.3m series A round in 2016, with commitments from Pritzker Group, Tribeca Venture Partners and Biomatics Capital.
